
CISCER®Cervical Cancer Methylation Test (PAX1/JAM3)
Dual-gene methylation test, empowering cervical cancer prevention
PAX1/JAM3 dual-gene combined test using non-invasive cervical exfoliated cell sampling, accurately identifying CIN2+ high-grade lesions for precise triage.
Recommended companion kits
Use the DNA Isolation and Purifying Kit (Beijing Medical Device No. 20210020) for DNA extraction and purification, followed by DNA Methylation-Lightning MagPrep (Beijing Medical Device No. 20200110) for bisulfite conversion.
Robust clinical data support
Based on multi-center registered clinical trials, sensitivity and specificity both reach industry-leading levels.
Who needs this test?
- Precision triage for HPV-positive individuals
- Women with mild cytological abnormalities (ASC-US)
- Cervical cancer screening for postmenopausal women
- Treatment response and recurrence monitoring for cervical lesions
How is it applied clinically?
- Opportunistic and population-based cervical cancer screening
- Colposcopy referral decisions after HPV-positive results
- Post-treatment follow-up for high-grade cervical lesions
- Women's health dual-screening programs at health checkup centers
Why choose us
Dual-gene (PAX1/JAM3) combined test with superior performance
Supported by multi-center study data with 10,000+ paired cases
Recommended by multiple domestic and international expert consensus and guidelines
Ongoing nationwide multi-center real-world studies
Frequently asked questions about this test
What is the CISCER test?
CISCER is a Class III in vitro diagnostic device (NMPA Reg. No. 20233400253) that detects PAX1/JAM3 dual-gene methylation in cervical exfoliated cells for early cervical cancer screening and triage of HPV-positive individuals.
How accurate is the CISCER test?
Registration clinical trial data (1,968 samples) show 89.60% sensitivity for CIN2+, 96.50% specificity, and 95.96% sensitivity for CIN3+, supported by a 10,000-sample multi-center real-world study.
Is the CISCER sampling procedure painful?
No. The test requires only cervical exfoliated cells collected non-invasively during a routine gynecological exam — no biopsy needed.
I tested HPV-positive. Should I also get the CISCER test?
Recommended. Most HPV infections are transient. CISCER methylation testing assesses cancer risk at the lesion level, helping identify who genuinely needs colposcopy referral and avoiding over-diagnosis and over-treatment.
Who is suitable for the CISCER test?
HPV-positive individuals, women with mild cytological abnormalities (ASC-US), postmenopausal women, and patients monitoring efficacy or recurrence before and after treatment for cervical lesions.
Request the IFU, clinical summary and pricing
Tell us your institution type and intended use. We reply within 1–2 business days with the documents below, and can arrange a technical call with our clinical team.
- IFU, registration certificate and sample requirements
- Clinical performance summary and published papers
- Distributor terms, kit configuration and logistics
The same methylation platform, two more cancers
CISPOLY covers cervical, endometrial and ovarian cancer with one non-invasive workflow.
Cervical Cancer Related Publications

Reply to: Comments on "Enhanced Diagnostic Accuracy of High-Grade Cervical Intraepithelial Neoplasia in Postmenopausal Women Through PAX1/JAM3 Methylation Analysis"
Journal: International Journal of Cancer
Affiliation: Changsha Blood Center
DOI: 10.1002/ijc.70484

Effectiveness analysis and clinical application potential exploration of combined detection of PAX1/JAM3 gene methylation in early diagnosis of cervical precancerous lesions
Journal: Clinical Epigenetics
Affiliation: Tumor Hospital Affiliated to Xinjiang Medical University
DOI: 10.1186/s13148-026-02095-z

PAX1/JAM3 methylation - a novel biomarker for early detection and accurate management of cervical adenocarcinoma
Journal: American Journal of Cancer Research
Affiliation: The 940th Hospital of Joint Logistics Support Force of PLA
DOI: 10.62347/SATU5579

Diagnostic testing accuracy of DNA methylation tests for detection of high-grade cervical intraepithelial neoplasia and cervical cancer: A systematic review and meta-analysis
Journal: European Journal of Cancer
Affiliation: Imperial College London
DOI: 10.1016/j.ejca.2026.116823

Association of PAX1/JAM3 gene methylation, HR-HPV, and TCT with high-grade cervical lesions in a high-risk cohort: a multinomial logistic regression analysis
Journal: BMC Women's Health
Affiliation: First Hospital of Hebei Medical University
DOI: 10.1186/s12905-026-04622-9

Preliminary study on PAX1/JAM3 methylation and HPV viral load in CIN3-like squamous cell carcinoma: Are there differences from CIN3 and early invasive carcinoma?
Journal: Clinical Epigenetics
Affiliation: Peking University People's Hospital
DOI: 10.1186/s13148-026-02201-1

Enhanced diagnostic accuracy of high-grade cervical intraepithelial neoplasia in postmenopausal women through PAX1/JAM3 methylation analysis
Journal: International Journal of Cancer
Affiliation: The First Hospital of Hunan University of Chinese Medicine
DOI: 10.1002/ijc.70245

Diagnostic value of PAX1/JAM3 gene methylation for cervical cancer in HR-HPV-infected women
Journal: Labeled Immunoassays and Clinical Medicine
Affiliation: Beijing Obstetrics and Gynecology Hospital, Capital Medical University (Beijing Maternal and Child Health Care Hospital)
DOI: 10.11748/bjmy.issn.1006-1703.2025.10.008

Application of PAX1/JAM3 dual-gene methylation in cervical cancer screening and treatment
Journal: International Journal of Obstetrics and Gynecology
Affiliation: The Second Affiliated Hospital of Shandong First Medical University
DOI: 10.12280/gjfckx.20250484

Preliminary study on the predictive value of PAX1 and JAM3 gene methylation in cervical exfoliated cells for cervical intraepithelial neoplasia
Journal: Journal of Hunan Normal University (Medical Sciences)
Affiliation: Changsha Maternal and Child Health Hospital

The performance of JAM3/PAX1 methylation in the diagnosis of high-grade squamous intraepithelial lesions for women with high-risk HPV infection
Journal: BMC cancer
Affiliation: The Third Xiangya Hospital of Central South University
DOI: 10.1186/s12885-024-13299-y

Triage performance of PAX1m/JAM3m in opportunistic cervical cancer screening of non-16/18 human papillomavirus-positive women: a multicenter prospective study
Journal: Clinical Epigenetics
Affiliation: Peking Union Medical College Hospital
DOI: 10.1186/s13148-024-01731-w

High-grade cervical lesions diagnosed by JAM3/PAX1 methylation in high-risk human papillomavirus-infected patients
Journal: Journal of Central South University (Medical Sciences)
Affiliation: The Third Xiangya Hospital of Central South University
DOI: 10.11817/j.issn.1672-7347.2023.230175

Reply to: Comments on "Enhanced Diagnostic Accuracy of High-Grade Cervical Intraepithelial Neoplasia in Postmenopausal Women Through PAX1/JAM3 Methylation Analysis"
Journal: International Journal of Cancer
Affiliation: Changsha Blood Center
DOI: 10.1002/ijc.70484

Effectiveness analysis and clinical application potential exploration of combined detection of PAX1/JAM3 gene methylation in early diagnosis of cervical precancerous lesions
Journal: Clinical Epigenetics
Affiliation: Tumor Hospital Affiliated to Xinjiang Medical University
DOI: 10.1186/s13148-026-02095-z

PAX1/JAM3 methylation - a novel biomarker for early detection and accurate management of cervical adenocarcinoma
Journal: American Journal of Cancer Research
Affiliation: The 940th Hospital of Joint Logistics Support Force of PLA
DOI: 10.62347/SATU5579

Diagnostic testing accuracy of DNA methylation tests for detection of high-grade cervical intraepithelial neoplasia and cervical cancer: A systematic review and meta-analysis
Journal: European Journal of Cancer
Affiliation: Imperial College London
DOI: 10.1016/j.ejca.2026.116823

Association of PAX1/JAM3 gene methylation, HR-HPV, and TCT with high-grade cervical lesions in a high-risk cohort: a multinomial logistic regression analysis
Journal: BMC Women's Health
Affiliation: First Hospital of Hebei Medical University
DOI: 10.1186/s12905-026-04622-9

Preliminary study on PAX1/JAM3 methylation and HPV viral load in CIN3-like squamous cell carcinoma: Are there differences from CIN3 and early invasive carcinoma?
Journal: Clinical Epigenetics
Affiliation: Peking University People's Hospital
DOI: 10.1186/s13148-026-02201-1

Enhanced diagnostic accuracy of high-grade cervical intraepithelial neoplasia in postmenopausal women through PAX1/JAM3 methylation analysis
Journal: International Journal of Cancer
Affiliation: The First Hospital of Hunan University of Chinese Medicine
DOI: 10.1002/ijc.70245

Diagnostic value of PAX1/JAM3 gene methylation for cervical cancer in HR-HPV-infected women
Journal: Labeled Immunoassays and Clinical Medicine
Affiliation: Beijing Obstetrics and Gynecology Hospital, Capital Medical University (Beijing Maternal and Child Health Care Hospital)
DOI: 10.11748/bjmy.issn.1006-1703.2025.10.008

Application of PAX1/JAM3 dual-gene methylation in cervical cancer screening and treatment
Journal: International Journal of Obstetrics and Gynecology
Affiliation: The Second Affiliated Hospital of Shandong First Medical University
DOI: 10.12280/gjfckx.20250484

Preliminary study on the predictive value of PAX1 and JAM3 gene methylation in cervical exfoliated cells for cervical intraepithelial neoplasia
Journal: Journal of Hunan Normal University (Medical Sciences)
Affiliation: Changsha Maternal and Child Health Hospital

The performance of JAM3/PAX1 methylation in the diagnosis of high-grade squamous intraepithelial lesions for women with high-risk HPV infection
Journal: BMC cancer
Affiliation: The Third Xiangya Hospital of Central South University
DOI: 10.1186/s12885-024-13299-y

Triage performance of PAX1m/JAM3m in opportunistic cervical cancer screening of non-16/18 human papillomavirus-positive women: a multicenter prospective study
Journal: Clinical Epigenetics
Affiliation: Peking Union Medical College Hospital
DOI: 10.1186/s13148-024-01731-w

High-grade cervical lesions diagnosed by JAM3/PAX1 methylation in high-risk human papillomavirus-infected patients
Journal: Journal of Central South University (Medical Sciences)
Affiliation: The Third Xiangya Hospital of Central South University
DOI: 10.11817/j.issn.1672-7347.2023.230175






















